Loading the player...
Immunotherapy Bests Surgery, Adjuvant Chemo in NSCLC
In the phase 3 IMpower010 trial, atezolizumab met its primary endpoint of significant disease-free survival improvement for patients with stage II-IIIA NSCLC.
Researchers found a significant disease-free survival benefit with atezolizumab compared with best supportive care after complete resection and adjuvant chemotherapy in patients with PD-L1 TC ≥1% stage II-IIIA NSCLC, according to a press release.
A total of 1,280 patients were enrolled with completely resected stage IB-IIIA NSCLC, with an ECOG performance status of 0-1.
Patients received up to 4 cycles of cisplatin-based chemotherapy, and 1,005 patients were randomized to atezolizumab 1200 mg every 3 weeks or best supportive care.
In the intent-to-treat population, median time from surgery to first atezolizumab treatment or best supportive care was 5.2 months an 5.1 months, respectively.
Disease-free survival was better with atezolizumab versus best supportive care across most disease stages, surgery types and chemotherapy regimens.
By MD /alert Staff
Researchers found a significant disease-free survival benefit with atezolizumab compared with best supportive care after complete resection and adjuvant chemotherapy in patients with PD-L1 TC ≥1% stage II-IIIA NSCLC, according to a press release.
A total of 1,280 patients were enrolled with completely resected stage IB-IIIA NSCLC, with an ECOG performance status of 0-1.
Patients received up to 4 cycles of cisplatin-based chemotherapy, and 1,005 patients were randomized to atezolizumab 1200 mg every 3 weeks or best supportive care.
In the intent-to-treat population, median time from surgery to first atezolizumab treatment or best supportive care was 5.2 months an 5.1 months, respectively.
Disease-free survival was better with atezolizumab versus best supportive care across most disease stages, surgery types and chemotherapy regimens.
By MD /alert Staff